{"schema_version":"secwatch.filing_event.v1","accession":"0001824293-26-000002","form_type":"8-K","ticker":"GRI","cik":"0001824293","company_name":"GRI Bio, Inc.","filed_at":"2026-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.368981+00:00","generated_at":"2026-05-16T11:14:56.172226+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"GRI Bio reports positive Phase 2a immune data for GRI-0621 in IPF","bullets":["Phase 2a data shows GRI-0621 reduces pro-fibrotic cytokines (IL-4, IL-13, IL-17A, IL-22, TGF-β) and increases anti-fibrotic IFN-γ in BAL and PBMC after 12 weeks.","Study met primary safety/tolerability endpoint; secondary endpoints suggest fibrosis reversal and lung repair, with twice as many subjects with no FVC decline vs standard of care.","35 subjects enrolled, 2:1 randomized to GRI-0621 4.5mg or placebo for 12 weeks; sub-study in 8 subjects examines immune cells in BAL fluid.","Company believes stockholders' equity exceeds $2.5M Nasdaq minimum after December 2025 public offering."],"urls":{"canonical":"https://secwatch.observer/filing/0001824293-26-000002","json":"https://secwatch.observer/filing/0001824293-26-000002.json","markdown":"https://secwatch.observer/filing/0001824293-26-000002.md","text":"https://secwatch.observer/filing/0001824293-26-000002.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1824293/000182429326000002/0001824293-26-000002-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1824293/000182429326000002/val-20260108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:14:56.172226+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}